224 related articles for article (PubMed ID: 14613022)
1. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
Jones SE
Semin Oncol; 2003 Oct; 30(5 Suppl 16):14-20. PubMed ID: 14613022
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Jones SE; Pippen J
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summaries: fulvestrant.
Bross PF; Cohen MH; Williams GA; Pazdur R
Oncologist; 2002; 7(6):477-80. PubMed ID: 12490735
[TBL] [Abstract][Full Text] [Related]
6. A new estrogen receptor antagonist--an overview of available data.
Jones SE
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant - a novel endocrine therapy for breast cancer.
Johnston SJ; Cheung KL
Curr Med Chem; 2010; 17(10):902-14. PubMed ID: 20156170
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
9. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Croxtall JD; McKeage K
Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant in postmenopausal women with advanced breast cancer.
Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
Morris C; Wakeling A
Endocr Relat Cancer; 2002 Dec; 9(4):267-76. PubMed ID: 12542403
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Chia S; Gradishar W
Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
[TBL] [Abstract][Full Text] [Related]
16. Current and future perspectives on fulvestrant.
Gradishar WJ; Sahmoud T
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S23-9. PubMed ID: 15865847
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK
J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982
[TBL] [Abstract][Full Text] [Related]
18. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]